Compare Comcast Corporation (CMCSA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Novartis AG — how do they compare? Comcast Corporation trades at $25.58 (market cap $89.43B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 3.3× Comcast Corporation's market cap, and Comcast Corporation pays the higher dividend (5.24%). Which is the better fit depends on your goals.
| CMCSA | NVS | |
|---|---|---|
Market Cap | $89.43B | $298.18B |
Sector | Media | Health |
52-Week High | $32.50 | $168.62 |
52-Week Low | $21.92 | $119.31 |
Enterprise Value | $172.15B | $339.50B |
Dividend Yield | 5.24% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $25.36, up 0.75% today, with strong technical momentum showing bullish moving averages and support at $25. The company demonstrates robust fundamentals with a low P/E of 8.13 and consistent earnings beats, including Q2 2026 EPS of $1.04 versus $0.97 expected. Recent expansion announcements in Florida and New Hampshire highlight ongoing growth initiatives.
CMCSA presents compelling value with discounted valuation multiples and a 55.74% analyst buy rating. Key opportunities include wireless growth and Peacock profitability, while risks involve competitive pressures and the planned NBCUniversal spinoff. The consensus price target of $27.78 suggests 9.5% upside potential from current levels.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
